Navigation Links
PRA International Exhibits at European Hematology Association Congress

RALEIGH, N.C., June 11 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, is exhibiting our significant hematology expertise and experience at the European Hematology Association's (EHA) 15th congress in Barcelona 10-13 June 2010.

At PRA's booth (#202), conference attendees can meet with our lead hematology expert, Ute Berger, M.D., to discuss the key issues and latest developments in hematology drug development. Also at booth 202, attendees can further explore our company's other comprehensive services.

PRA's vice president of Medical Affairs and EHA's former chairwoman, Dr. Berger is board certified in hematology, oncology, and internal medicine. With 18 years of clinical experience, she is also certified by the European Society of Medical Oncology (ESMO). She possesses close contact with many therapeutic experts and investigative sites in hematology and oncology, and offers a unique perspective on this research field.

A recognized leader in hematology and oncology, PRA has participated in 96 hematology trials in 18 indications in 54 countries over the last five years as well as 275 oncology trials in 24 indications in 50 countries over the same period. Our services have contributed to the approval of many leading and innovative cancer drugs, and more than 70% of our clinical staff is experienced in hematology and oncology.

For more information about EHA's conference and our exhibit, navigate to and click on "Events."

About PRA International

PRA International conducts clinical trials in more than 75 countries across 6 continents and provides services through all phases of clinical development. PRA performs studies in all therapeutic areas, with specialization in Oncology/Hematology, Neurosciences, Respiratory/Allergy, Cardiovascular and Infectious Diseases. In the last five years, PRA has supported over 2,700 clinical trials through its 37 global offices.

PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT enable our project teams to deliver consistent and on-time performance for our clients. This unique PRA philosophy - THE PERSONAL ELEMENT - recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.

To learn more about PRA International, please visit, email or call our Global Headquarters at +1 (919) 786-8200.

SOURCE PRA International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
3. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
4. Arrow International Files and Mails Definitive Proxy Materials
5. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
6. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
7. Viragen International to Reverse Split Its Common Stock
8. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
9. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
10. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
11. Biosafety and Biosecurity International Conference 2007 to be held in Abu Dhabi from November 12 to 14
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT . ... a corporate overview. th Annual Oppenheimer Healthcare Conference ... a.m. PT . Jim Mazzola , vice president of ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the "Company"), ... Toronto Stock Exchange, confirms that as of the date ... that would cause the recent movements in the Company,s ... About Aeterna Zentaris Inc. . ... Zentaris is a specialty biopharmaceutical company engaged in developing ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
(Date:10/29/2015)... 2015 NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... a leading marketplace to discover and buy innovative ... wallet on StackSocial for this holiday season.   ... "Company"), a biometric authentication company focused on the ...
Breaking Biology News(10 mins):